Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1045-1051

  Shukeir, Nicholas ^a   Garde, Seema ^b   Wu, Jinzi J ^b   Panchal, Chandra ^b   Rabbani, Shafaat A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Apoptosis; Hypercalcemia of malignancy; Prostate cancer; Prostate secretory protein

Indexed keywords

CALCIUM; COMPLEMENTARY DNA; PARATHYROID HORMONE RELATED PROTEIN; PROSTATIC SECRETORY PROTEIN; PROSTATIC SECRETORY PROTEIN 94; PROTEIN PCK3145; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; DOSE RESPONSE; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; LUMBAR VERTEBRA; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SPINE METASTASIS;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CALCIUM; CELL LINE, TUMOR; HUMANS; MALE; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RATS;

EID: 27644448034     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00002     Document Type: Review

References (58)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001; 51:15-36.
2. Brawer MK. Screening for prostate cancer. Semin Surg Oncol 2000; 18:29-36.
3. Ryan CJ, Small EJ. Small progress in detection and treatment of prostate cancer. Curr Opin Oncol 2005; 17:257-260.
4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45.
5. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 2002; 9:61-73.
6. Schroder FH. Prostate cancer: natural history and surgical treatment of localised disease. Eur J Cancer 2001; 37(Suppl 7):S127-S136.
7. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9:295-306.
8. Fusi A, Procopio G, Della Torre S, Ricotta R, Bianchini G, Salvioni R, et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 2004; 90:535-546.
9. Moore CN, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr Opin Urol 2005; 15:157-162.
10. Fournier G. Treatment of hormone-refractory prostate carcinoma. Eur Urol 1996; 30(Suppl 1):32-37.
11. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995; 18:51-64.
12. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993; 13:443-449.
13. Bagi CM. Skeletal implications of prostate cancer. J Musculoskelet Neuronal Interact 2003; 3:112-117.
14. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003; 97:779-84.
15. Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat Res 2004; 118:197-212.
16. Brubaker KD, Corey E, Brown LG, Vessela RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004; 91:151-160.
17. Thomas BG, Hamdy FC. Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3:283-285.
18. Achbarou A, Kaiser S, Tremblay G, St-Marie LG, Brodt P, Goltzman D, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54: 2372-2377.
19. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer 1997; 80:1581-1587.
20. Rabbani SA, Desjardin J, Bell AW, Banville D, Mazar A, Henkin J, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058-1064.
21. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992; 267:14151-14156.
22. Asadi F, Kukreja S. Parathyroid hormone-related protein in prostate cancer. Crit Rev Eukaryot Gene Expr 2005; 15:15-28.
23. Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum Pathol 1996; 27: 1319-1323.
24. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Tagger H, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237:893-896.
25. Martin TJ, Suva LJ. Parathyroid hormone-related protein in hypercalcaemia of malignancy. Clin Endocrinol 1989; 31:631-647.
26. Cramer SD, Peehl DM, Edgar MG, Wong ST, Deftos LJ, Feldman D. Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 1996; 29:20-29.
27. Dougherty KM, Blomme EA, Koh AJ, Henderson JE, Pienta KJ, Rosol TJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999; 59:6015-6022.
28. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005; 327:468-472.
29. Iddon J, Bundred NJ, Hoyland J, Downey SE, Baird P, Salter D, et al. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol 2000; 191: 170-174.
30. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 1999; 80:257-264.
31. Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol TJ, McCauley LK. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999; 39:187-197.
32. Mundle SD, Sheth NA. In vivo suppression of pituitary and circulatory follicle stimulating hormone by human seminal plasma inhibin. Indian J Exp Biol 1991; 29:310-314.
33. Abrahamsson PA, Lilja H. Three predominant prostatic proteins. Andrologia 1990; 22(Suppl 1):122-131.
34. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL, Chan FL. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999; 41:99-109.
35. Kwong J, Xuan JW, Choi HL, Chan PS, Chan FL. PSP94 (or beta-microseminoprotein) is a secretory protein specifically expressed and synthesized in the lateral lobe of the rat prostate. Prostate 2000; 42: 219-229.
36. Thota A, Karajgikar M, Duan W, Gabril MY, Chan FL, Wong YC, et al. Mouse PSP94 expression is prostate tissue-specific as demonstrated by a comparison of multiple antibodies against recombinant proteins. J Cell Biochem 2003; 88:999-1011.
37. Brar A, Mbikay M, Sirois F, Fournier S, Seidah NG, Chretien M. Localization of the human prostatic secretory protein PSP94 and its mRNA in the epithelial cells of the prostate. J Androl 1988; 9:253-260.
38. Schaffner DL, Barrios R, Shaker MR, Rajagopalan S, Huang SL, Tindall DJ, et al. Transgenic mice carrying a PSArasT24 hybrid gene develop salivary gland and gastrointestinal tract neoplasms. Lab Invest 1995; 72:283-290.
39. Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, Koropatnick J, et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 2002; 9:1589-1599.
40. Liu AY, Bradner RC, Vessella RL. Decreased expression of prostatic secretory protein PSP94 in prostate cancer. Cancer Lett 1993; 74:91-99.
41. Vanaja DK, Cheville JC, Iturria SJ, Toung CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63:3877-3882.
42. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, Saito Y. Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 1999; 38:278-284.
43. Garde SV, Sheth AR, Venkatesan VM, Panchal CJ, Porter AT, Grignon DJ. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). Cancer Lett 1994; 78:11-17.
44. Mundle SD, Sheth NA. Suppression of DNA synthesis and induction of apoptosis in rat prostate by human seminal plasma inhibin (HSPI). Cell Biol Int 1993; 17:587-594.
45. Vanage GR, Garde SV, Sheth AR, Gopalkrishnan K. Passive immunization against prostatic 'inhibin' peptide as a male contraceptive. Int J Androl 1992; 15:114-126.
46. Shah MG, Sheth AR. Similarities in the modulation of pituitary and prostatic FSH by inhibin and related peptides. Prostate 1991; 18:1-8.
47. Bandivdekar AH, Devasagayam TP, Pradhan DS, Joseph DR, Hurkadli KS. Suppression of lipid peroxidation in human spermatozoa by prostatic inhibin. Arch Androl 1989; 22:217-221.
48. Phadke M, Vijayalakshmi S, Sheth AR. Evidence for the presence of specific receptors for inhibin in human prostate. Indian J Exp Biol 1982; 20:419-420.
49. Yang JP, Finkelman MA, Clarke MW. Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP. J Urol 1998; 160:2240-2244.
50. Yang JP, Baijal-Gupta M, Garde SV, Fraser JE, Finkelman MA, Clarke MW. Identification of binding proteins for PSP94 in human prostate adenocarcinoma cell lines LNCaP and PC-3. Prostate 1998; 35:11-17.
51. Reeves JR, Xuan JW, Arfanis K, Morin C, Garde SV, Ruiz MT, et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J 2005; 385:105-114.
52. Woodruff TK. Hope, hypothesis, and the inhibin receptor. Does specific inhibin binding suggest there is a specific inhibin receptor? Endocrinology 1999; 140:3-5.
53. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003; 63: 2072-2028.
54. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 2004; 64:5370-5377.
55. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001; 42:326-336.
56. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002; 277:35035-35043.
57. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40:539-551.
58. Girvan AR, Chang P, van Huizen I, Moussa M, Xuan JW, Stitt L, et al. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 2005; 65: 719-723.